CN117100621A - 一种抗菌纳米纤维干面膜及其制备方法 - Google Patents
一种抗菌纳米纤维干面膜及其制备方法 Download PDFInfo
- Publication number
- CN117100621A CN117100621A CN202311376373.4A CN202311376373A CN117100621A CN 117100621 A CN117100621 A CN 117100621A CN 202311376373 A CN202311376373 A CN 202311376373A CN 117100621 A CN117100621 A CN 117100621A
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- spinning
- mask
- cellulose
- dry mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 74
- 239000002121 nanofiber Substances 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000001913 cellulose Substances 0.000 claims abstract description 55
- 229920002678 cellulose Polymers 0.000 claims abstract description 55
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 34
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 13
- 238000009987 spinning Methods 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000011550 stock solution Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 229940069521 aloe extract Drugs 0.000 claims description 3
- 229960000271 arbutin Drugs 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 102000018511 hepcidin Human genes 0.000 claims description 2
- 108060003558 hepcidin Proteins 0.000 claims description 2
- 229940066919 hepcidin Drugs 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 206010040880 Skin irritation Diseases 0.000 abstract description 5
- 239000000835 fiber Substances 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 230000036556 skin irritation Effects 0.000 abstract description 4
- 231100000475 skin irritation Toxicity 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 101800003310 Hepcidin-25 Proteins 0.000 description 5
- 102400001151 Hepcidin-25 Human genes 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920000433 Lyocell Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000579120 Coliiformes Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
- D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0069—Electro-spinning characterised by the electro-spinning apparatus characterised by the spinning section, e.g. capillary tube, protrusion or pin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0076—Electro-spinning characterised by the electro-spinning apparatus characterised by the collecting device, e.g. drum, wheel, endless belt, plate or grid
- D01D5/0084—Coating by electro-spinning, i.e. the electro-spun fibres are not removed from the collecting device but remain integral with it, e.g. coating of prostheses
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0092—Electro-spinning characterised by the electro-spinning apparatus characterised by the electrical field, e.g. combined with a magnetic fields, using biased or alternating fields
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
针对现有的干面膜抗菌成分可能造成的皮肤刺激、敏感等问题,本发明提供了一种抗菌纳米纤维干面膜及其制备方法。本发明首先将马来酰亚胺功能化的氨基化纤维素进行抗菌肽修饰,使其表面带有更多正电荷,能够吸附并破坏细菌细胞膜,从而实现高效的抗菌效果,然后再结合静电纺丝纳米纤维制备技术,将其制备成抗菌纳米纤维干面膜,不仅可以使得纤维表面带的抗菌肽在纳米尺度上进行均匀的分布,实现优异的抗菌效果,而且本发明是通过化学修饰的方法将抗菌肽修饰于高分子的纤维素骨架上,在面膜使用过程中不会以小分子形态游离到面膜有效成分中,从而减少了抗菌成分可能造成的皮肤刺激、敏感问题。
Description
技术领域
本发明属于护肤用品技术领域,具体涉及一种抗菌纳米纤维干面膜及其制备方法。
背景技术
随着人们生活水平的提高和对美容健康的关注度增加,面膜作为一种重要的美容产品,已经成为人们日常美容护肤的必备品之一。然而,传统的面膜在生产过程中需要添加大量的防腐剂,以防止面膜在储存和使用过程中被微生物污染,从而导致面膜的品质下降,甚至对人体健康产生威胁。此外,由于防腐剂的存在,有些面膜使用后可能会导致皮肤过敏或刺激,影响用户的使用体验。
近年来,一种新型面膜——干面膜,已经受到越来越多消费者的青睐。相比于传统面膜,干面膜更加节省防腐剂的使用,因为它不需要添加大量水分,从而降低了细菌滋生的风险,同时也减轻了肌肤负担。虽然干面膜可以减少防腐剂的使用,但是也不是完全不需要防腐剂的。因为干面膜在制作、储存和使用过程中,都有可能受到微生物的污染,导致面膜变质或失效。因此,为了保证干面膜的安全性和有效性,还是需要添加少量的防腐剂,以抑制微生物的生长和繁殖。因此,如何在保证抗菌性的同时,进一步减少防腐剂的使用,是当前面膜行业亟需解决的问题。
CN113318066A公开了一种用于护肤的脱敏冻干面膜及其生产工艺,其中用于护肤的脱敏冻干面膜包括基布载体层和以冷冻干燥形式附着在所述基布载体层上的冻干膜层,其特征在于:所述冻干膜层中包括冻干功效物,所述冻干功效物包括抗敏修复组合物、抗衰老组合物、保湿美白组合物和植物抗菌剂。
CN115715744A公开了一种碳点基纳米酶抗菌抗氧化冻干面膜,纳米酶由富含氧空位的铜、钼掺杂碳点(Cu, Mo/CDs)及铜、碘掺杂碳点(Cu, I/CDs)组成,Cu, Mo/CDs具有强模拟过氧化酶特性,在过硫酸盐存在下,会产生羟基自由基和超氧自由基,并进入细菌内切断核酸,使蛋白质失活,破坏细胞膜完整性,而氧空位也能促进产生更多的活性氧(ROS),从而对革兰氏致病菌及其耐药菌有较强的杀菌效果。
上述两个专利申请分别采用植物抗菌剂和碳点基纳米酶抗菌防腐,从而减少了传统防腐剂的使用,然而所用抗菌剂均没有修饰于面膜基底上,使用过程中有在面部残留以及渗透皮肤的风险。
发明内容
针对上述问题,本发明提供了一种抗菌纳米纤维干面膜及其制备方法。本发明首先将马来酰亚胺功能化的氨基化纤维素进行抗菌肽修饰,使其表面带有更多正电荷,能够吸附并破坏细菌细胞膜,从而实现高效的抗菌效果,然后再结合静电纺丝纳米纤维制备技术,将其制备成抗菌纳米纤维干面膜,不仅可以使得纤维表面带的抗菌肽在纳米尺度上进行均匀的分布,实现优异的抗菌效果,并且可以确保面膜成分与皮肤贴合,从而提高了有效成分的渗透性和吸收性,采用本发明的抗菌纳米纤维干面膜,不需要再另外添加防腐剂。
此外,抗菌肽通过点击化学反应修饰到纤维素骨架上,而纤维素是一种高分子聚合物,因此在面膜使用过程中抗菌肽不会以小分子形态游离到面膜有效成分中,避免了抗菌肽这一阳离子抗菌剂对于皮肤渗透的可能性,进一步减少了抗菌成分可能造成的皮肤刺激、敏感的问题。
本发明的技术方案是:一种抗菌纳米纤维干面膜的制备方法,包括以下步骤:
1)抗菌肽修饰的氨基化纤维素的制备
将马来酰亚胺功能化的氨基化纤维素溶解于磷酸盐缓冲液中,再加入含有巯基的抗菌肽,进行混合搅拌反应,反应完全后用半透膜进行去离子水透析,再冻干获得固体的抗菌肽修饰的氨基化纤维素;
2)纺丝原液的配制
配制浓度1~3% (w/v)抗菌肽修饰的氨基化纤维素的水溶液,在其中加入3~6% (w/v)聚乙烯吡咯烷酮(PVP)作为增塑剂,加入0.1~1%(w/v)的保湿剂及0.1~3%(w/v)小分子面膜功效成分,搅拌均匀后得到纺丝原液;
3)静电纺丝制备抗菌纳米纤维干面膜
将步骤2)的纺丝原液加入静电纺丝机中,设置纺丝电压为30~50 kV、纺丝温度为15~20 ℃,以防静电的面膜布为纺丝基底,纺丝喷头到基底的距离为18~25 cm,打开控制开关,车速0.1~1m/min,纺丝原液成丝喷到基底上获得纳米纤维干面膜,纳米纤维直径10-1000nm,成膜厚度10~500μm。
优选的,所述步骤1)含有巯基的抗菌肽可以为抗菌肽CysHHC10、抗菌肽Hepcidin等。所述马来酰亚胺功能化的氨基化纤维素与含巯基的抗菌肽的质量比为1:2~4,优选1:3。所述半透膜优选MWCO 3.5 kDa。所述混合搅拌反应优选搅拌反应20~28小时。
优选的,所述步骤2)的保湿剂为小分子量玻尿酸(Mw 40000-80000 Da)、氨基酸和麦芽糖醇中的至少一种,优选至少包含小分子量玻尿酸。优选的,所述小分子面膜功效成分可以为维生素C、烟酰胺、熊果苷、芦荟提取物等中的至少一种,根据面膜的功效进行添加。
优选的,所述步骤3)的防静电的面膜布,其克重为:20 g/m2,材质为:30 %铜氨纤维和70 %天丝。
优选的,马来酰亚胺功能化的氨基化纤维素的制备方法为:将氨基化纤维素溶解于浓度0.8~1.2%的稀盐酸溶液中;将6-马来酰亚胺基己酸、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDCI)和N-羟基丁二酰亚胺(NHS)溶解在二甲亚砜中;然后将两种溶液混合搅拌反应;反应完成后将混合物用半透膜进行去离子水透析,得到马来酰亚胺功能化的氨基化纤维素的水溶液,再经冻干得到马来酰亚胺功能化的氨基化纤维素固体。所述氨基化纤维素、6-马来酰亚胺基己酸、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基丁二酰亚胺的质量比为10:9.5~10.5:7.5~8.5:7.5~8.5,优选为10:10:8:8。
本发明干面膜的抗菌性由修饰抗菌肽的氨基化纤维素提供,所述纳米纤维干面膜由静电纺丝法制得。
本发明的技术原理:
纤维素是一种天然、无毒和具有抗菌性的多糖,氨基化纤维素能够通过骨架上的氨基与细菌表面的负电荷发生作用而表现出抗菌活性,也就是说,氨基的含量决定了氨基化纤维素的抗菌效果。但是,氨基化纤维素自身的抗菌能力有限,提高氨基化纤维素的抗菌活性的最有效方法是增加氨基化纤维素上的正电荷,通过对官能团进行适当的功能化处理。
抗菌肽是一种天然存在于动植物体内的短肽分子,具有广谱抗菌和抗病毒活性。它们通过与细菌膜表面的负电荷相互作用,改变膜的结构并引起破坏,从而实现杀菌作用。相比于传统的抗菌剂,抗菌肽具有更广泛的抗菌谱和更高的抗菌能力。
本发明通过6-(马来酰亚胺基)己酸与氨基化纤维素上的氨基进行酰化反应,将马来酰亚胺接枝到氨基化纤维素上;然后抗菌肽上的巯基通过点击反应接枝到马来酰亚胺上,从而得到抗菌肽修饰的氨基化纤维素,反应示意图如图1所示。
本发明的技术效果是:
(1)通过采用静电纺丝纳米纤维制备技术,使抗菌肽在纳米尺度上均匀地分散于纳米纤维干面膜表面,这一尺度远远小于细菌的一般尺寸(0.5~5 微米),大大提高了面膜的抗菌效率,可以减少现有防腐抗菌剂的使用造成的皮肤敏感、过敏等问题。
(2)通过化学修饰的方法将抗菌肽修饰于高分子的纤维素骨架上,在面膜使用过程中抗菌肽不会以小分子形态游离到面膜有效成分中,避免了抗菌肽这一阳离子抗菌剂对于皮肤渗透的可能性,减少了抗菌成分可能造成的皮肤刺激、敏感的问题。
(3)采用静电纺丝纳米纤维制备技术制备出的抗菌纳米纤维干面膜具有超高的比表面积,可以增强有效成分的渗透性和吸收性。
(4)纳米纤维使得面膜更加贴合肌肤,更加舒适。
可见,区别于背景技术中给出的2个专利申请,本发明采用了纳米纤维技术制备面膜基材,抗菌肽在纳米尺度上均匀地分散于纳米纤维干面膜表面,这一尺度远远小于细菌的一般尺寸,大大提高了面膜的抗菌效率,可以减少现有防腐抗菌剂的使用造成的皮肤敏感、过敏等问题。此外,区别与上述专利申请,本发明通过化学修饰的方法将抗菌肽修饰于高分子的纤维素骨架上,在面膜使用过程中抗菌肽不会以小分子形态游离到面膜有效成分中,避免了抗菌肽这一阳离子抗菌剂对于皮肤渗透的可能性,进一步减少了抗菌成分可能造成的皮肤刺激、敏感的问题。
综上,本发明的纳米纤维干面膜基于修饰抗菌肽的氨基化纤维素进行抗菌,不需要另外加入防腐剂,不仅降低了对肌肤的刺激,还可以提高干面膜的抗菌能力。同时,本发明通过采用静电纺丝纳米纤维制备技术,制备出的纳米纤维干面膜不仅可以提高抗菌效果,还可以增强有效成分的渗透性和吸收性。并且纳米纤维干面膜更加贴合肌肤,更加舒适。本发明同时保证了面膜成分的安全性和稳定性。因此,本发明具有广泛的应用前景,在护肤行业和医疗行业中都具有重要的应用价值。
附图说明
图1为抗菌肽修饰的氨基化纤维素的合成反应示意图;
图2为实施例1制备的抗菌纳米纤维干面膜的电镜图;
图3为实施例1抗菌纳米纤维干面膜与大肠杆菌/金黄色葡萄球菌共培养的细胞存活率图;
图4为实施例1抗菌纳米纤维干面膜的细胞相容性结果图;
图5为实施例2制备的抗菌纳米纤维干面膜的电镜图;
图6为实施例2抗菌纳米纤维干面膜与大肠杆菌/金黄色葡萄球菌共培养的细胞存活率图;
图7为实施例2抗菌纳米纤维干面膜的细胞相容性结果图。
具体实施方式
为更进一步阐述本发明为实现预定发明目的所采取的技术手段及功效,以下结合附图及较佳实施例,对本发明的具体实施方式、特征及其功效详细说明如下所示。
本发明实施例使用的氨基化纤维素采用BH3/THF溶液对氰乙基纤维素进行非均相还原法制备而成(参见:Mohammad L. Hassan. Preparation and Thermal Stability ofNew Cellulose-Based Poly(propylene imine) and Poly(amido amine) HyperbranchedDerivatives. Journal of Applied Polymer Science, 2006, 101:2079-2087),具体为:取1 g 氰乙基纤维素加入15 mL的1M BH3/THF溶液中,加热回流12 h,产物过滤后用碳酸氢钠饱和溶液处理,用水和甲醇洗涤,60℃干燥。
本实施例马来酰亚胺功能化的氨基化纤维素(MHCS)的合成方法如下:将10 g氨基化纤维素溶解于0.5 L 浓度1%的稀盐酸溶液中,将10 g 6-马来酰亚胺基己酸、8 g 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDCI)和8 g N-羟基丁二酰亚胺(NHS)溶解在0.2L的二甲亚砜中;然后将两种溶液混合搅拌反应24小时,将混合物用MWCO 3.5 kDa的半透膜进行去离子水透析3天,得到马来酰亚胺功能化氨基化纤维素的水溶液。最终,通过冻干法得到马来酰亚胺功能化的氨基化纤维素(MHCS)固体。
实施例1:
一种抗菌纳米纤维干面膜的制备方法,包括以下步骤:
1)修饰抗菌肽CysHHC10的氨基化纤维素的合成
将5 g的马来酰亚胺功能化的氨基化纤维素固体溶解于0.2 L pH 7.4的磷酸盐缓冲液中,再加入15 g 含有巯基的抗菌肽CysHHC10;混合搅拌反应24小时后将混合物用MWCO3.5 kDa的半透膜进行去离子水透析3天。最终,通过冻干法得到修饰抗菌肽CysHHC10的氨基化纤维素;
2)纺丝原液的配制
配制浓度1 %(w/v)修饰抗菌肽CysHHC10的氨基化纤维素的水溶液,在其中加入6%(w/v)医用级的聚乙烯吡咯烷酮(PVP)作为增塑剂,加入1 %(w/v)的小分子量玻尿酸作为保湿剂,加入0.1 %(w/v)维生素C、0.05 %(w/v)烟酰胺作为抗氧化美白成分,搅拌均匀后得到纺丝原液;
3)将上述纺丝原液加入静电纺丝机中,纺丝电压为30 kV、纺丝温度为15 ℃,以防静电处理的面膜布(克重为:20 g/m2,材质为:30 %铜氨纤维和70 %天丝)作为纺丝基底,纺丝喷头到基底的距离为18 cm,车速1m/min,成膜厚度10μm。
实施例1制备的抗菌纳米纤维干面膜的扫描电子显微镜的照片如图2所示,从图中可以看到:本实施例制备的抗菌纳米纤维干面膜具有良好的粒径均一性,纳米纤维直径在100-200 nm。
取2 mg抗菌纳米纤维干面膜分别与1 mL 106CFU/mL的大肠杆菌(E. coli)或金黄色葡萄球菌(S. aureus)细菌悬液进行共培养20 h,然后将0.1ml细菌培养液涂在琼脂平板上,并置于37℃培养箱中过夜。使用自动菌落计数器测量细菌菌落数,并计算细菌存活率。为了对比抗菌性能,制备了含有相同比例的未修饰抗菌肽(也不需要马来酰亚胺功能化)的氨基化纤维素纳米纤维干面膜。抗菌结果如图3所示(每个处理3次重复,取平均值),氨基化纤维素由于表面氨基带正电荷,具有一定的抗菌性。而抗菌肽CysHHC10的修饰进一步提高了纳米纤维干面膜的抗菌特性。表明该抗菌纳米纤维干面膜对于革兰氏阳性菌与阴性菌均具有优异的抑菌能力。
通过MTT法测试所制备抗菌纳米纤维干面膜的细胞毒性。将NIH 3T3细胞在添加5%胎牛血清的DMEM培养基中培养24h,然后吸出培养基,再加入抗菌纳米纤维干面膜浓度依次为78、156、313、625、1250、2500 μg/mL的DMEM培养基继续培养24h,用MTT法测试细胞毒性,实验结果如图4所示(每个处理3次重复,取平均值),结果表明:该抗菌纳米纤维干面膜在2500 μg/mL的高浓度下细胞存活率可以达到>92%,表现出优异的生物相容性。
实施例2:
一种抗菌纳米纤维干面膜的制备方法,包括以下步骤:
1)修饰抗菌肽Hepcidin-25的氨基化纤维素的合成
将5 g的马来酰亚胺功能化氨基化纤维素固体溶解于0.2 L pH 7.4的磷酸盐缓冲液中,再加入15 g 含有巯基的抗菌肽Hepcidin-25。混合搅拌反应24小时后用MWCO 3.5kDa的半透膜进行去离子水透析3天。最终,通过冻干法得到修饰抗菌肽Hepcidin-25的氨基化纤维素;
2)纺丝原液的配制
配制浓度2 %(w/v)修饰抗菌肽Hepcidin-25的氨基化纤维素的水溶液,在其中加入5% (w/v)医用级的聚乙烯吡咯烷酮(PVP)作为增塑剂,加入0.5 %(w/v)的小分子量玻尿酸、0.3 %(w/v)的三甲基甘氨酸(NMF-50,中广生物)、0.2 %(w/v)的麦芽糖醇作为保湿剂,加入0.1 %(w/v)维生素C、0.05 %(w/v)熊果苷作为抗氧化美白成分,再加入1%(w/v) 的芦荟提取物,搅拌均匀后得到纺丝原液;
3)将上述纺丝原液加入静电纺丝机中,纺丝电压为50kV、纺丝温度为18 ℃、以防静电处理的面膜布(克重为:20 g/m2,材质为:30 %铜氨纤维和70 %天丝)作为纺丝基底,纺丝喷头到基底的距离为22 cm,车速0.3 m/min,成膜厚度90 μm。
实施例2所制备的抗菌纳米纤维干面膜的扫描电子显微镜的照片如图5所示,从图中可以看到:本实施例制备的抗菌纳米纤维干面膜具有良好的粒径均一性,纳米纤维直径在200-300 nm。
取2 mg抗菌纳米纤维干面膜与1 mL 106CFU/mL的大肠杆菌(E. coli)或金黄色葡萄球菌(S. aureus)细菌悬液进行共培养20 h。然后将0.1ml细菌培养液涂在琼脂平板上,并置于37℃培养箱中过夜,使用自动菌落计数器测量细菌菌落数,并计算细菌存活率。为了对比抗菌性能,制备了含有相同比例的未修饰抗菌肽(也不需要马来酰亚胺功能化)的氨基化纤维素纳米纤维干面膜,抗菌结果如图6所示,氨基化纤维素由于表面氨基带正电荷,具有一定的抗菌性。对比实施例1,纺丝液中氨基化纤维素含量更高,并且纺丝车速低,成膜厚度更高,因而抗菌性能有所提升。而抗菌肽Hepcidin-25的修饰进一步提高了抗菌纳米纤维干面膜的抗菌特性,对比实施例1,由于抗菌肽含量更高,因而体现出更好的抗菌性。表明该抗菌纳米纤维干面膜对于革兰氏阳性菌与阴性菌均具有优异的抑菌能力。
通过MTT法测试所制备的抗菌纳米纤维干面膜的细胞毒性。将NIH 3T3细胞在添加5%胎牛血清的DMEM培养基中培养24h,然后吸出培养基,再加入抗菌纳米纤维干面膜浓度为78、156、313、625、1250、2500 μg/mL的DMEM培养基继续培养24h,用MTT法测试细胞毒性。实验结果如图7所示,结果表明:该抗菌纳米纤维干面膜在2500 μg/mL的高浓度下细胞存活率可以达到>87%,对比实施例1,细胞相容性轻微下降,是由于抗菌肽的含量增加的结果,但该结果仍然表明该抗菌纳米纤维干面膜具有优异的生物相容性。
Claims (8)
1.一种抗菌纳米纤维干面膜的制备方法,其特征是,包括以下步骤:
1)抗菌肽修饰的氨基化纤维素的制备
将马来酰亚胺功能化的氨基化纤维素溶解于磷酸盐缓冲液中,再加入含有巯基的抗菌肽,进行混合搅拌反应,反应完全后用半透膜进行去离子水透析,再冻干获得抗菌肽修饰的氨基化纤维素;
2)纺丝原液的配制
配制浓度为1~3%的抗菌肽修饰的氨基化纤维素的水溶液,在其中加入3~6%聚乙烯吡咯烷酮作为增塑剂,再加入0.1~1%的保湿剂及0.1~3%的小分子面膜功效成分,搅拌均匀后得到纺丝原液;所述百分比均为质量体积比;
3)静电纺丝制备抗菌纳米纤维干面膜
将步骤2)的纺丝原液加入静电纺丝机中,以防静电的面膜布为纺丝基底,纺丝原液成丝喷到基底上获得抗菌纳米纤维干面膜。
2. 如权利要求1所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,步骤3)中,设置纺丝电压为30~50 kV,纺丝温度为15~20 ℃,纺丝喷头到基底的距离为18~25 cm,静电纺丝过程中车速0.1~1m/min。
3.如权利要求1所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,所述含有巯基的抗菌肽为抗菌肽CysHHC10或者抗菌肽Hepcidin。
4.如权利要求1所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,所述小分子面膜功效成分为维生素C、烟酰胺、熊果苷和芦荟提取物中的至少一种。
5.如权利要求1所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,所述保湿剂为小分子量玻尿酸、氨基酸和麦芽糖醇中的至少一种。
6.如权利要求1所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,步骤3)中纺丝原液成丝喷到基底上,成膜厚度为10~500μm。
7.如权利要求1-6中任一项所述的一种抗菌纳米纤维干面膜的制备方法,其特征是,所述马来酰亚胺功能化的氨基化纤维素的制备方法为:将氨基化纤维素溶解于浓度0.8~1.2%的稀盐酸溶液中;将6-马来酰亚胺基己酸、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基丁二酰亚胺溶解在二甲亚砜中;然后将两种溶液混合搅拌反应;反应完成后将混合物用半透膜进行去离子水透析,再经冻干得到马来酰亚胺功能化的氨基化纤维素。
8.权利要求1-6中任一项制备方法所制备的抗菌纳米纤维干面膜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311376373.4A CN117100621B (zh) | 2023-10-24 | 2023-10-24 | 一种抗菌纳米纤维干面膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311376373.4A CN117100621B (zh) | 2023-10-24 | 2023-10-24 | 一种抗菌纳米纤维干面膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117100621A true CN117100621A (zh) | 2023-11-24 |
CN117100621B CN117100621B (zh) | 2024-01-09 |
Family
ID=88813284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311376373.4A Active CN117100621B (zh) | 2023-10-24 | 2023-10-24 | 一种抗菌纳米纤维干面膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117100621B (zh) |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060063157A (ko) * | 2004-12-07 | 2006-06-12 | 대한민국(관리부서:국립수산과학원) | 넙치 유래의 항균성 펩타이드 헵시딘 |
CN102061303A (zh) * | 2010-11-26 | 2011-05-18 | 厦门大学 | 两种海洋动物抗菌肽基因的融合表达产物及其制备方法 |
CN104207948A (zh) * | 2014-08-18 | 2014-12-17 | 贵州捷欣合金技术开发有限公司 | 一种纺丝液及其用于制备纳米纤维膜的方法 |
CN106311154A (zh) * | 2015-06-30 | 2017-01-11 | 青岛蓝农谷农产品研究开发有限公司 | 一种抗菌性纤维吸附膜的制备方法 |
KR20180039393A (ko) * | 2016-10-10 | 2018-04-18 | 한국해양과학기술원 | 극지 어류 유래의 신규한 항생 펩타이드 |
CN108203879A (zh) * | 2017-12-29 | 2018-06-26 | 东华大学 | 一种基于巯基-马来酰亚胺点击化学的棉织物的抗菌整理方法 |
CN109984950A (zh) * | 2018-12-06 | 2019-07-09 | 上海益好纳米科技有限公司 | 一系列免洗全吸收型纳米纤维功能面膜及其制备方法 |
CN110028781A (zh) * | 2019-04-29 | 2019-07-19 | 中国科学院长春应用化学研究所 | 一种自修复水性聚氨酯/纤维素纳米晶复合材料及其制备方法 |
CN110025826A (zh) * | 2019-05-08 | 2019-07-19 | 苏州大学附属第二医院 | 引导骨组织再生膜、制备方法及应用 |
CN112263566A (zh) * | 2020-09-24 | 2021-01-26 | 中国药科大学 | 白蛋白结合型缺氧氧化双响应性复合纳米粒、制备方法及用途 |
CN112294661A (zh) * | 2020-06-01 | 2021-02-02 | 苏州逸纪杰电子科技有限公司 | 基于纤维素纤维的高保湿面膜 |
CN112608389A (zh) * | 2020-11-23 | 2021-04-06 | 中国林业科学研究院林产化学工业研究所 | 一种乙基纤维素基自修复聚合物及其制备方法 |
CN113081862A (zh) * | 2021-04-12 | 2021-07-09 | 长春工业大学 | 一种透明质酸复合静电纺丝面膜的制备方法 |
CN113195487A (zh) * | 2018-10-12 | 2021-07-30 | 杭州多禧生物科技有限公司 | 2,3-二氨基琥珀酰基偶联物连接子 |
CN113648413A (zh) * | 2021-06-29 | 2021-11-16 | 南开大学 | 超分子光活性金属纳米抗菌药物的制备方法 |
CN114569488A (zh) * | 2022-02-18 | 2022-06-03 | 宁波糖聚新材料有限责任公司 | 一种抑菌肽修饰纳米纤维素水凝胶、制备方法及其应用 |
CN115382002A (zh) * | 2022-08-25 | 2022-11-25 | 东华大学 | 一种兼具智能抗菌及感染指示的海绵敷料及其制备方法 |
CN115487337A (zh) * | 2022-09-23 | 2022-12-20 | 奥精医疗科技股份有限公司 | 一种皮肤修复用敷料贴及其制备方法 |
CN115873233A (zh) * | 2022-12-09 | 2023-03-31 | 成都爱睿康乐医疗器械有限公司 | 一种多功能多肽聚合物及其制备方法和应用 |
-
2023
- 2023-10-24 CN CN202311376373.4A patent/CN117100621B/zh active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060063157A (ko) * | 2004-12-07 | 2006-06-12 | 대한민국(관리부서:국립수산과학원) | 넙치 유래의 항균성 펩타이드 헵시딘 |
CN102061303A (zh) * | 2010-11-26 | 2011-05-18 | 厦门大学 | 两种海洋动物抗菌肽基因的融合表达产物及其制备方法 |
CN104207948A (zh) * | 2014-08-18 | 2014-12-17 | 贵州捷欣合金技术开发有限公司 | 一种纺丝液及其用于制备纳米纤维膜的方法 |
CN106311154A (zh) * | 2015-06-30 | 2017-01-11 | 青岛蓝农谷农产品研究开发有限公司 | 一种抗菌性纤维吸附膜的制备方法 |
KR20180039393A (ko) * | 2016-10-10 | 2018-04-18 | 한국해양과학기술원 | 극지 어류 유래의 신규한 항생 펩타이드 |
CN108203879A (zh) * | 2017-12-29 | 2018-06-26 | 东华大学 | 一种基于巯基-马来酰亚胺点击化学的棉织物的抗菌整理方法 |
CN113195487A (zh) * | 2018-10-12 | 2021-07-30 | 杭州多禧生物科技有限公司 | 2,3-二氨基琥珀酰基偶联物连接子 |
CN109984950A (zh) * | 2018-12-06 | 2019-07-09 | 上海益好纳米科技有限公司 | 一系列免洗全吸收型纳米纤维功能面膜及其制备方法 |
CN110028781A (zh) * | 2019-04-29 | 2019-07-19 | 中国科学院长春应用化学研究所 | 一种自修复水性聚氨酯/纤维素纳米晶复合材料及其制备方法 |
CN110025826A (zh) * | 2019-05-08 | 2019-07-19 | 苏州大学附属第二医院 | 引导骨组织再生膜、制备方法及应用 |
CN112294661A (zh) * | 2020-06-01 | 2021-02-02 | 苏州逸纪杰电子科技有限公司 | 基于纤维素纤维的高保湿面膜 |
CN112263566A (zh) * | 2020-09-24 | 2021-01-26 | 中国药科大学 | 白蛋白结合型缺氧氧化双响应性复合纳米粒、制备方法及用途 |
CN112608389A (zh) * | 2020-11-23 | 2021-04-06 | 中国林业科学研究院林产化学工业研究所 | 一种乙基纤维素基自修复聚合物及其制备方法 |
CN113081862A (zh) * | 2021-04-12 | 2021-07-09 | 长春工业大学 | 一种透明质酸复合静电纺丝面膜的制备方法 |
CN113648413A (zh) * | 2021-06-29 | 2021-11-16 | 南开大学 | 超分子光活性金属纳米抗菌药物的制备方法 |
CN114569488A (zh) * | 2022-02-18 | 2022-06-03 | 宁波糖聚新材料有限责任公司 | 一种抑菌肽修饰纳米纤维素水凝胶、制备方法及其应用 |
CN115382002A (zh) * | 2022-08-25 | 2022-11-25 | 东华大学 | 一种兼具智能抗菌及感染指示的海绵敷料及其制备方法 |
CN115487337A (zh) * | 2022-09-23 | 2022-12-20 | 奥精医疗科技股份有限公司 | 一种皮肤修复用敷料贴及其制备方法 |
CN115873233A (zh) * | 2022-12-09 | 2023-03-31 | 成都爱睿康乐医疗器械有限公司 | 一种多功能多肽聚合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117100621B (zh) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mehrabani et al. | Preparation of biocompatible and biodegradable silk fibroin/chitin/silver nanoparticles 3D scaffolds as a bandage for antimicrobial wound dressing | |
El-Aassar et al. | Electrospun polyvinyl alcohol/pluronic F127 blended nanofibers containing titanium dioxide for antibacterial wound dressing | |
Ulubayram et al. | Nanofibers based antibacterial drug design, delivery and applications | |
Haghju et al. | Affecting parameters on fabrication of β-D-galactosidase immobilized chitosan/poly (vinyl alcohol) electrospun nanofibers | |
Wang et al. | Immobilization of lysozyme on layer-by-layer self-assembled electrospun films: Characterization and antibacterial activity in milk | |
CN110229247B (zh) | 基于海藻酸衍生物电纺纳米复合纤维膜医用敷料及其制备方法 | |
CN110747534A (zh) | 一种抗菌多糖纤维材料及其制备方法 | |
Min et al. | Enzyme-responsive food packaging system based on pectin-coated poly (lactic acid) nanofiber films for controlled release of thymol | |
CN112169007A (zh) | 一种基于静电纺丝的抗菌纤维膜的制备方法 | |
CN112451418A (zh) | 一种含有脂质体的纳米纤维面膜及其制备方法 | |
Ullah et al. | Functionalized bacterial cellulose microparticles for drug delivery in biomedical applications | |
AKTÜRK et al. | Collagen/PEO/gold nanofibrous matrices for skin tissue engineering | |
CN111602672B (zh) | 一种抗菌纳米材料及其制备方法和应用 | |
Korniienko et al. | Functional and biological characterization of chitosan electrospun nanofibrous membrane nucleated with silver nanoparticles | |
Rajora et al. | Evaluating neem gum-polyvinyl alcohol (NGP-PVA) blend nanofiber mat as a novel platform for wound healing in murine model | |
CN117100621B (zh) | 一种抗菌纳米纤维干面膜及其制备方法 | |
Padil et al. | “Green” polymeric electrospun fibers based on tree-gum hydrocolloids: fabrication, characterization and applications | |
CN115105629B (zh) | 一种抗菌水凝胶及其制备方法和应用 | |
CN112111809A (zh) | 一种聚γ-谷氨酸/壳聚糖/纳米氧化锌抗菌复合纤维的制备方法 | |
CN112972750B (zh) | 一种抗菌消毒纳米纤维医用敷料及其制备方法 | |
Sanjarnia et al. | Nanocomposite chitosan dressing incorporating polydopamine‑copper Janus nanoparticle | |
CN112807443B (zh) | 一种多重协同的抗菌纳米前药 | |
CN114887058A (zh) | 基于光敏性纳米复合物的递送系统及其制备方法、应用 | |
Varava et al. | Antimicrobial electrospun chitosan nanofibrous membranes functionalized with silver nanoparticles | |
Evelyna et al. | Preparation of nanocellulose-alginate nanocomposites for chlorhexidine digluconate drug carrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |